Video

Dr. Gafita on the Opportunity for 177Lu-PSMA-617 in mCRPC

Andrei Gafita, MD, discusses available therapies for men with advanced castration-resistant prostate cancer.

Andrei Gafita, MD, of the Department of Nuclear Medicine at Klinikum Rechts der Isar at the Technical University Munich, discusses available therapies for men with advanced castration-resistant prostate cancer (CRPC).

Multiple retrospective, large series studies, as well as phase 2 data have led to the ongoing, phase 3 VISION trial, which is now aiming to result in the FDA approval of 177Lutetium-prostate-specific membrane antigen (LuPSMA), says Gafita. Men with prostate cancer are initially treated with an androgen deprivation therapy and hormone treatment, although most of them eventually progress. They then enter into a lethal phenotype of disease for metastatic CRPC.

For those with this advanced, late-stage prostate cancer, several treatments have been approved. Chemotherapy agents, such as docetaxel and cabazitaxel, are available, as well as the new generation of antiandrogen treatments, such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi). Radiopharmaceuticals, such as radium-223 dichloride (Xofigo), which is a nuclear medicine treatment, is also available, as well as PARP inhibitors.

Unfortunately, in this state of disease, most patients progress on treatment and all standard treatments are exhausted. This is where LuPSMA comes into play; it can serve as an option for patients who have progressed on all other conventional treatment modalities, concludes Gafita.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity